Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration

PURPOSE: To compare the efficacy and safety of 1.25 mg versus 2.5 mg intravitreal bevacizumab (IVB) for treatment of choroidal neovascularization (CNV) associated with agerelated macular degeneration (AMD). METHODS: In this randomized clinical trial, consecutive patients with active CNV associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Modarreszadeh, Mehdi, Naseripour, Masood, Ghasemi-Falavarjani, Khalil, Nikeghbali, Aminollah, Hashemi, Masih, Parvaresh, Mohammad-Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ophthalmic Research Center 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589230/
https://www.ncbi.nlm.nih.gov/pubmed/23479531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589230/
https://www.ncbi.nlm.nih.gov/pubmed/23479531

Ejemplares similares